GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (NAS:CNTG) » Definitions » Institutional Ownership

Centogene NV (Centogene NV) Institutional Ownership : 0.15% (As of May. 01, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Centogene NV Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Centogene NV's institutional ownership is 0.15%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Centogene NV's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Centogene NV's Float Percentage Of Total Shares Outstanding is 42.97%.


Centogene NV Institutional Ownership Historical Data

The historical data trend for Centogene NV's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV Institutional Ownership Chart

Centogene NV Historical Data

The historical data trend for Centogene NV can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 0.24 0.24 0.24 0.24 0.24 0.15 0.15 0.15 0.15 0.15

Centogene NV Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Centogene NV (Centogene NV) Business Description

Traded in Other Exchanges
Address
Am Strande 7, Rostock, MV, DEU, 18055
Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company operates in three segments: pharmaceutical, diagnostics, and COVID-19. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.